Symbiotec Pharmalab Limited
SYMBIOTEC · NSE · ₹1,611 a share (close of 13 Nov 2026)
Available company data, source links and archived checks for Symbiotec Pharmalab Limited. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.
Net profit was ₹51.7 crore.
Quarter ended 2026-09-30 · consolidated · Company filing
Recorded quarterly figures
| Quarter | Revenue / income | YoY |
Profit | YoY | Net margin | Source |
|---|
| Sep 2026 | Revenue: ₹280 cr | — | Net profit: ₹52 cr | — | 18.5% | Company filing source |
| Jun 2026 | Revenue: ₹218 cr | — | Net profit: ₹14 cr | — | 6.4% | Company filing source |
YoY means change from the same quarter a year earlier.
— means no comparable figure is available. Older entries with incomplete source
details have not been revalidated under the current checks.
Who holds it — from the filings
Satwani Holdings LLP 15.3%Rosewood Investments 14.1%Anil Satwani 11.8%Business Excellence Trust Iii - India Business Excellence Fund Iii 10.2%Mirae Asset Aggressive Hybrid Fund 6.0%register as filed
2026-09-30
Filing timeline — what the company told the exchange
- Analysts/Institutional Investor Meet/Con. Call Updates. Symbiotec Pharmalab Limited has informed the Exchange about Transcript
Company disclosure · 12 Nov 2026 · document
- Analysts/Institutional Investor Meet/Con. Call Updates. Symbiotec Pharmalab Limited has informed the Exchange about Schedule of meet
Company disclosure · 12 Nov 2026 · document
- Symbiotec Pharmalab Limited has informed the Exchange about Copy of Newspaper Publication
Company disclosure · 06 Nov 2026 · document
- Analysts/Institutional Investor Meet/Con. Call Updates. Symbiotec Pharmalab Limited has informed the Exchange about Link of Recording
Company disclosure · 06 Nov 2026 · document
- Symbiotec Pharmalab Limited has informed the Exchange about General Updates ((Symbiotec Signs 10-Year Take-Or-Pay Agreement To Manufacture Fermentation-Based Al
Company disclosure · 06 Nov 2026 · document
- The Monitoring Agency Report issued by the CARE Edge Ratings, Monitoring Agency, appointed by the Company for the utilisation and application of funds raised th
Company disclosure · 05 Nov 2026 · document
- Press Release. Symbiotec Pharmalab Limited has informed the Exchange regarding a press release dated November 05, 2026, titled "Investor Release being issued by
Company disclosure · 05 Nov 2026 · document
- Symbiotec Pharmalab Limited has informed the Exchange about Investor Presentation
Company disclosure · 05 Nov 2026 · document
Follow this company without reading every document yourself.
Keep its available filings, dated fact checks and disclosure alerts together.
Your saved country sets your market and its research schedule.
Start free — first week on us →
India ₹149/month · Rest of world US$4.99/month after the free trial · research, not investment
advice · cancel any time